anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Herein disclosed are a methods and systems of SAMMI—a machine learning-based workflow that uses human annotations as labels for training models—used to predict human-based annotations for drug discovery. SAMMI receives an input to a model trained using human-annotated data, wherein the human-annotated data comprises at least one annotation associated with a triage-progressability annotation of whether to progress the input for the drug discovery. SAMMI also receives a set of features. The set of features are associated with the input, the model, and the triage-progressability of the input. The set of features is applied to the model to predict whether the input is triage-progressible. A model output is provided based on the prediction.
1521632 Dental alloys W V YOUDELIS 5 Feb 1976 [20 Feb 1975 13 June 1975] 04651/76 Heading C7A A powder composite, suitable for the production of dental amalgams having improved properties and using significantly less mercury in amalgamating comprises (a) 70-99À5 wt. per cent of a silver-tin alloy powder containing 75 Ag, 25 Sn, with optionally up to 8% of the silver-tin alloy being replaced by 0À6% Cu and 0À2% Zn used with (b) 0À5-30 wt. per cent powdered Indium using this composite powder, the amalgamation with mercury may be carried out using mercuryto-powder ratios of 0À5 to 0À75:1 as opposed to the normal ratios of 1 to 1À6:1. A modification of the process uses a powder composite containing a dispersion phase silver-based alloy, which remains non-amalgamated and in discrete particle form in the final amalgam. A suitable composition of this composite powder has (a) 45-50 wt. per cent of the powdered silver-tin alloy mentioned above with (b) 40-45 wt. per cent of a powdered silver-based alloy containing at least 50% Ag which is not amalgamatable with mercury and (c) 8-12 wt. per cent of powdered In. Preferably, the dispersion phase alloy (b) is silvercopper, containing 28% Cu. It is stated that the improvement in properties is achieved by ensuring the In present is neither alloyed with the other components of the composite nor with the mercury prior to amalgamation.
The study will be separated into three cohorts: Motion Correction, Parametric Imaging, and MAP Reconstruction. The motion correction (Aim 1) cohort will involve a group of 30 subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system in the PET/CT Molecular Imaging Research Center in Charlton 6 of Mayo Clinic Rochester. The data gathered from this cohort will assess the effectiveness of motion correction software for patients undergoing PET brain scans. The parametric imaging (Aim 2) cohort will include 30 subjects that have recently undergone a brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this cohort is to assess the data acquisition and image processing workflow for parametric analysis of brain and whole body scans. The MAP Reconstruction Cohort (Aim 3) is a retrospective study to assess the quality of PET images reconstructed with maximum a posteriori (MAP) reconstruction algorithm.
The device (10) comprises a hot gaseous medium, a treatment zone (14), in which the material to be treated is subjected to an admission with the hot gaseous medium, a blower (16) for circulating the gaseous medium, a separator, which is separatable from the circulating medium during the treatment of the developing fine particles, and a wrapped deflecting element, which is arranged in a helical-shaped line and through which a stream of the gaseous medium with fine particles is dividable into a radially external first partial stream and internal second partial stream. The device (10) comprises a hot gaseous medium, a treatment zone (14), in which the material to be treated is subjected to an admission with the hot gaseous medium, a blower (16) for circulating the gaseous medium, a separator, which is separatable from the circulating medium during the treatment of the developing fine particles and is formed as a centrifugal separator provided with an inlet and two outlets, and a wrapped deflecting element, which is arranged in a helical-shaped line and through which a stream of the gaseous medium with fine particles developing over the inlet is dividable into a radially external first partial stream enriched with the fine particles supplyable to a first outlet and into an internal second partial stream released from the fine particles supplyable to a second outlet. The centrifugal separator is arranged in the treatment zone. The second partial stream released from the fine particles is supplied to the blower for circulation. The first partial stream enriched with the fine particles is delivered from the treatment zone. The treatment zone has a series of suspended tubes. The circulating gaseous medium is supplyable to a superior end of the suspended tubes and a conveying groove carrying a particulate biological or pharmacological material is arranged under a lower-lying end of the suspended tubes. A thermal energy loaded additional gaseous medium is supplied to the circulating gaseous medium. The quantity of the supplied medium corresponds to the quantity of the delivered first partial stream. The thermal energy loaded additional gaseous medium is downstreamly supplied to the centrifugal separator and is upstreamly supplied to the blower. Collecting channels, over which the gaseous medium is collected after contacting with the material, are laterally arranged to the conveying groove and are supplyable to the centrifugal separator. The suspended tubes flows into the collecting channel depend of the bottom, over which a collector (18) is arranged. The collector is connected with a suction side (20) of the blower. A gas burner is arranged at the collector and supplies the thermal energy loaded additional gaseous medium to the collector. The collecting channel flows into a cassette, in which a multiple of centrifugal separators are arranged. The first partial stream enriched with the fine particles is collectively delivered over a common outlet and is supplied to a further separator. The first partial stream is supplied to a cascade at the further separator.
The prevalence of adolescent myopia is remarkably increasing. Previous studies have indicated that an unhealthy diet is a risk factor for myopia. However, the link between diet-related inflammation and myopia is unclear. To explore their correlation, we used dietary inflammation index (DII) that is a parameter to quantify the inflammatory potential of diet, to reveal the relationship between DII and myopia in adolescents. We extracted sociodemographic data, information of diets and eye refractive status of adolescents from National Health and Nutrition Examination Survey (NHANES) for period 1999-2008. Dietary intake data was used to calculate DII scores, which were then categorized into quartiles. Multivariable regression models and subgroup analyses were conducted to investigate the association between DII and myopia. Subsequently, smoothed curve analyses were conducted to discern the trend of correlation between DII and myopia across diverse population. A total of 7191 juveniles aged at 12 to 18 years with complete information were included in our study, consisting 3367 participants with diagnosis of myopia. Among these participants, a trend towards an increasing prevalence of myopia was observed with a higher DII. After adjusting for all covariates, stratified logistic regression analyses showed that among the population aged in 16 to 18 years old or with 9-11th grade educational level, the prevalence of myopia was significantly increased with higher DII score (OR = 1.06, 95% CI = 1.01, 1.11, P = 0.006; OR = 1.06, 95% CI = 1.01, 1.11, P = 0.010). In the two subgroups, participants in the highest quartile of DII had a 31.00% higher risk of myopia and a higher 27.00% risk of myopia respectively, compared to those in the lowest quartile of DII. Our results revealed an increasing trend in the prevalence of myopia with increased DII score in adolescents. Particularly, DII was positively associated with the risk of myopia among the population aged in 16 to 18 years old and with 9-11th grade educational level.
BACKGROUND: The term rapidly progressive dementia (RPD) with Lewy bodies (rpDLB) is used for DLB patients who develop a rapidly progressive neurological syndrome and have reduced survival. Here, we characterise the clinical, neuropathological, and molecular characteristics of a large rpDLB neuropathological series.
METHODS: We included all RPD patients with a disease duration < 4 years submitted to our prion disease referral centre between 2003 and 2022 who showed Lewy body pathology (LBP) in limbic or neocortical stages as primary neuropathological diagnosis, had no systemic condition justifying the rapid deterioration and were previously neurologically unimpaired. Clinical features were retrieved and compared with Creutzfeldt-Jakob disease (CJD) and rapidly progressive Alzheimer's disease (rpAD) cohorts. Neuropathological and genetic (whole exome sequencing, APOE genotyping, and C9orf72 repeat expansion analysis) characteristics of rpDLB patients were systematically investigated. We scored semi-quantitatively the LBP load and performed a α-synuclein (αSyn) RT-QuIC seeding amplification assay (SAA) on cerebrospinal fluid (CSF) and tenfold serially diluted brain homogenates from different brain areas in rpDLB patients and typical long-lasting Lewy body disease (LBD) with dementia patients as control group.
RESULTS: RpDLB patients were older (p = 0.047) and presented more cognitive fluctuations (p = 0.005), visual hallucinations (p = 0.020), neuropsychiatric symptoms (p = 0.006) and seizures (p = 0.032), and fewer cerebellar (p < 0.001) and visual (p = 0.004) signs than CJD ones. Delirium onset was more common than in both CJD (p < 0.001) and rpAD (p = 0.008). Atypical LBD signs (pyramidal, myoclonus, akinetic mutism) were common. All tested patients were positive by CSF αSyn SAA. Concomitant pathologies were common, with only four cases showing relatively "pure" LBP. LBP load and αSyn seeding activity measured through αSyn RT-QuIC SAA were not significantly different between rpDLB patients and typical LBD. We found a likely pathogenic variant in GBA in one patient.
CONCLUSIONS: Our results indicate that: 1) rpDLB exhibits a distinct clinical signature (2) CSF αSyn SAA is a reliable diagnostic test; 3) rpDLB is a heterogeneous neuropathological entity that can be underlain by both widespread pure LBP, or multiple copathologies 4) rpDLB is likely not sustained by distinct αSyn conformational strains; 5) genetic defects may, at least occasionally, contribute to the poor prognosis in these patients.
The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including nortriptyline hydrochloride, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular changes (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of nortriptyline hydrochloride with MAOIs intended to treat psychiatric disorders is contraindicated. Nortriptyline hydrochloride should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking nortriptyline hydrochloride. Nortriptyline hydrochloride should be discontinued before initiating treatment with the MAOI (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION). 

If concomitant use of nortriptyline hydrochloride with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

Treatment with nortriptyline hydrochloride and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
* Do not use if the container has been damaged, the protective seal and/or rubber cap have been entered, or the upper white layer is absent (may indicate the microspheres have been damaged and may result in poor or no echo contrast).
  * Invert the OPTISON vial and gently rotate to resuspend the microspheres. This process will allow the product to come to room temperature (20° to 25°C or 68° to 77°F) before use.
  * Inspect the vial for complete resuspension. Do not use if the suspension appears to be clear rather than opaque and milky-white.
  * Vent the OPTISON vial with a sterile vent spike or with a sterile 18 gauge needle before withdrawing the OPTISON suspension into the injection syringe.
  * Do not inject air into the vial.
  * Use the product within one minute of suspension. If one minute is exceeded, resuspend by inverting and gently rotating the microsoheres in the syringe. Failure to adequately resuspend OPTISON may cause inadequate delivery of the microspheres, and may result in inadequate contrast.
This observational, retrospective study uses the PharMetrics and MarketScan US health care claim insurance database to assess the occurrence of venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute myocardial infarction in current users of ORTHO EVRA (norelgestromin and ethinyl estradiol transdermal contraceptive patch) compared to current users of levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol, with special attention to duration of use. PharMetrics is a United States based, ongoing longitudinal database with information on around 55 million covered lives going back as far as 1995. It is made up of data contributed by managed care plans throughout the United States and it contains information on paid claims for pharmaceuticals, medical diagnoses and procedures as well as demographic information on all subjects. There will be 3 sets of cases reflecting women who have a first-time recorded claim for an ICD-9 diagnosis of the following during the study period: (1) deep vein thrombosis (blood clot), pulmonary embolism, or cerebral venous sinus thrombosis, venous thrombotic event (VTE) with hospitalization, a visit to the emergency room or positive indication of VTE from diagnostic test results, at any time during the study period and who had subsequent multiple claims for anticoagulant treatment. The requirement for multiple prescriptions for anticoagulation therapy was used to provide evidence that the original diagnosis of VTE was confirmed. (2) ischemic stroke and who were hospitalized, or (3) acute myocardial infarction (heart attack) or acute coronary revascularization and who were hospitalized. Three separate sets of controls will be identified for each outcome. Planned analysis will estimate the relative risk of idiopathic (unknown cause) ischemic stroke or myocardial infarction, and another analysis will estimate the relative risk of idiopathic VTE. Conditional logistic regression will be used. Analyses will be stratified by calendar year. The analyses will be repeated including non-idiopathic cases of VTE, ischemic stroke, and acute myocardial infarction. Each transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol is worn for 1 week for 3 consecutive weeks; the fourth week is patch-free. Triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol is taken for 21 consecutive days followed by no pill or an inert pill for 7 days. Duration of use can vary. NOTE: The study was conducted in two parts. This study, CR014383, represents the first portion of the study. Study CR012022, NCT00377988, represents the second portion of the extended study.
The present invention provides methods and compositions for the stimulation of immune responses. In particular, the invention provides methods and compositions for enhancing an immune response to one or more antigens. Compositions and methods of the invention are useful for the treatment and/or prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites, as well as the treatment and/or prevention of cancer and malignant diseases. Compositions and methods of the invention include one or more antigens/immunogens together with an adjuvant formulation comprising an emulsion delivery system in combination with one or more immunostimulatory compounds (e.g., a compound that stimulates the innate immune system (e.g., a toll-like receptor antagonist (e.g., synthetic oligodeoxynucleotides (ODN)))) that enhance immune responses to the one or more antigens/immunogens when administered to a subject. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.
BACKGROUND: One in 3 patients relapse after antidepressant discontinuation. Thus, the prevention of relapse after achieving remission is an important component in the long-term management of major depressive disorder. However, no clinical or other predictors are established. Frontal reactivity to sad mood as measured by functional magnetic resonance imaging has been reported to relate to relapse independently of antidepressant discontinuation and is an interesting candidate predictor.
METHODS: Patients (n = 56) who had remitted from a depressive episode while taking antidepressants underwent electroencephalography (EEG) recording during a sad mood induction procedure prior to gradually discontinuing their medication. Relapse was assessed over a 6-month follow-up period. Thirty five healthy control participants were also tested. Current source density of the EEG power in the alpha band (8-13 Hz) was extracted and alpha asymmetry was computed by comparing the power across 2 hemispheres at frontal electrodes (F5 and F6).
RESULTS: Sad mood induction was robust across all groups. Reactivity of alpha asymmetry to sad mood did not distinguish healthy control participants from patients with remitted major depressive disorder on medication. However, the 14 (25%) patients who relapsed during the follow-up period after discontinuing medication showed significantly reduced reactivity in alpha asymmetry compared with patients who remained well. This EEG signal provided predictive power (69% out-of-sample balanced accuracy and a positive predictive value of 0.75).
CONCLUSIONS: A simple EEG-based measure of emotional reactivity may have potential to contribute to clinical prediction models of antidepressant discontinuation. Given the very small sample size, this finding must be interpreted with caution and requires replication in a larger study.
The European Society of Cardiology issued updated syncope guidelines in 2018 which included recommendations for managing syncope in the emergency department (ED) setting. However, these guidelines lack detailed process-oriented instructions regarding the fact that ED syncope patients initially present with a transient loss of consciousness (TLOC), which can have a broad spectrum of causes. This study aims to establish a European consensus on the general process of the workup and care for patients with suspected syncope and provides rules for sufficient and systematic management of the broad group of syncope (initially presenting as TLOC) patients in the ED. A variety of European diagnostic and therapeutic standards for syncope patients were reviewed and summarized in three rounds of a modified Delphi process by the European Society for Emergency Medicine syncope group. Based on a consensus statement, a detailed process pathway is created. The primary outcome of this work is the presentation of a universal process pathway for the structured management of syncope patients in European EDs. The here presented extended event process chain (eEPC) summarizes and homogenizes the process management of European ED syncope patients. Additionally, an exemplary translation of the eEPC into a practice-based flowchart algorithm, which can be used as an example for practical use in the ED, is provided in this work. Syncope patients, initially presenting with TLOC, are common and pose challenges in the ED. Despite variations in process management across Europe, the development of a universally applicable syncope eEPC in the ED was successfully achieved. Key features of the consensus and eEPC include ruling out life-threatening causes, distinguishing syncope from nonsyncopal TLOCs, employing syncope risk stratification categories and based on this, making informed decisions regarding admission or discharge.
Not participating in the intervention. Participants will complete the baseline questionnaire battery only and the investigational team will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.